Technical Analysis for VAL - Valirx Plc

Grade Last Price % Change Price Change
D 29.23 -0.92% -0.27
VAL closed up 1.72 percent on Monday, January 17, 2022, on 37 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical VAL trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish -0.92%
Inside Day Range Contraction -0.92%
Wide Bands Range Expansion -0.92%
Oversold Stochastic Weakness -0.92%
Shooting Star Candlestick Bearish 0.79%
Slingshot Bearish Bearish Swing Setup 0.79%
Multiple of Ten Bearish Other 0.79%
Wide Bands Range Expansion 0.79%
Oversold Stochastic Weakness 0.79%
Narrow Range Bar Range Contraction 3.47%
Older End-of-Day Signals for VAL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 6 hours ago
2x Volume Pace about 10 hours ago
1.5x Volume Pace about 10 hours ago
Down 2% about 11 hours ago
10 DMA Resistance about 11 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Valirx Plc Description

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.


Sector: Healthcare
Industry: Biotechnology
Keywords: Engineering Pharmaceutical Biotechnology Medicine Pipe Clinic Life Sciences Disease Cancer Oncology Clinical Trial Biopharmaceutical Biomarker Biomarkers Drug Development Cancer Screening Chemical Pathology Companion Diagnostic Prostate Cancer Treatment Of Cancer

Is VAL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 65.0
52 Week Low 17.26
Average Volume 1,128,092
200-Day Moving Average 26.57
50-Day Moving Average 33.17
20-Day Moving Average 32.95
10-Day Moving Average 30.35
Average True Range 2.85
ADX 14.86
+DI 22.33
-DI 25.09
Chandelier Exit (Long, 3 ATRs) 35.96
Chandelier Exit (Short, 3 ATRs) 36.72
Upper Bollinger Bands 41.35
Lower Bollinger Band 24.55
Percent B (%b) 0.29
BandWidth 50.99
MACD Line -1.51
MACD Signal Line -0.94
MACD Histogram -0.5648
Fundamentals Value
Market Cap 19.14 Million
Num Shares 64.9 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -59.00
Price-to-Sales 0.00
Price-to-Book 5.78
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.75
Resistance 3 (R3) 31.67 30.83 31.38
Resistance 2 (R2) 30.83 30.26 30.88 31.25
Resistance 1 (R1) 30.17 29.91 30.50 30.25 31.12
Pivot Point 29.33 29.33 29.50 29.38 29.33
Support 1 (S1) 28.67 28.76 29.00 28.75 27.88
Support 2 (S2) 27.83 28.41 27.88 27.75
Support 3 (S3) 27.17 27.83 27.63
Support 4 (S4) 27.25